IPO of a start-up which offers independence to the blind
Having initially successfully raised funds in 2011, in 2014 Pixium Vision was seeking additional financing to accelerate its development
Pixium Vision's aim is to offer greater independence and a better quality of life to people who have lost their sight. Founded in 2011, this medical technology company develops innovative vision restoration systems (VRS). This French start-up is seeking to gain approval in 2015 for its first-generation VRS, called IRIS®.
For Societe Generale, the partner of choice of small and medium-sized Medtech/Biotech companies, supporting this technological and human venture was an obvious choice.
When Pixium Vision launches an IPO
Having initially successfully raised funds in 2011, in 2014 Pixium Vision was seeking additional financing to accelerate its development. Accompanied by Societe Generale, the start-up launched an IPO on the Euronext market in Paris. Carried out within a difficult market environment, this Initial Public Offering was a major success. The funds raised through the IPO will allow Pixium Vision to finance the clinical development and commercial launch of IRIS® in Europe and the United States.
Tailor-made solutions set up by Societe Generale
Pixium is expected to gain approval for its first IRIS® system by the end of 2015. This will allow the company to launch clinical trials of its second VRS, PRIMA®, as of 2016.
Pixium Vision was especially receptive to Societe Generale's commitment to our project for the future." Bernard Gilly, Chairman of Pixium Vision